Crossmark

Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement

Crossref DOI link: https://doi.org/10.1007/s00277-026-06953-x

Published Online: 2026-04-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Frigeni, Marco

Algarotti, Alessandra

Salmoiraghi, Silvia

Belotti, Clara

Milani, Martina

Pavoni, Chiara

Spinelli, Orietta

Gotuzzo, Irene

Rambaldi, Alessandro

Lussana, Federico
License Information

Text and Data Mining valid from 2026-04-10

Version of Record valid from 2026-04-10
More Information

Article History

Received: 15 January 2026

Accepted: 12 March 2026

First Online: 10 April 2026

Declarations

:

: Ethics committee approval was not required for this study, as it is a single case report. All procedures were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments. Written informed consent for publication of this case report and any accompanying images was obtained from the patient.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below